Curi Bio launches Mantarray Platform for analysis of 3D Engineered Muscle Tissues
Curi Bio launches Mantarray Platform for analysis of 3D engineered muscle tissue in the development of new therapeutics
pharma
Synapse Medicine closes €7 million round for drug safety platform
Synapse Medicine, the medical intelligence platform developer, has raised €7 million in a round led by MACSF
Recursion Pharmaceuticals $121 million Series C for AI drug discovery
Recursion Pharmceuticals has closed a $121 million Series C funding round, led by Scottish Mortgage Investment Trust, with participation from new and all prior institutional investors. The funds will be invested to continue building Recursion’s AI-enabled drug discovery platform, as well as to develop capabilities to accelerate new chemical entity chemistry and predict safety pharmacology. Recursion […]
Webit 2019 Health Summit roundup
There isn’t any aspect of healthcare that isn’t being transformed by technology. The health-related technologies on display reflected the work that is being done to prevent illness, to deliver more effective treatments, and to reduce the growing cost of healthcare.
UK strength in genomics offset by weakness across life sciences
Statistics published today in the UK by the Department of Health, the Office of Life Sciences and the Department for Business, reveal a mixed picture with an overall modest increase in life sciences economic activity in the ten years from 2009 to 2018.
Schrödinger closes USD 85 million funding round from Gates Foundation and others
The Bill and Melinda Gates Foundation and WuXi AppTec’s Corporate Venture Fund have led an $85 million funding round into Schrödinger. The company produces a computational platform for drug discovery, which it also uses for its own research.
AI drug trials to scale up in 2019
Predictions are two a penny at this time of year, and no one will hold those who make the predictions to account. Tractica, a market intelligence agency, has put out a white paper with predictions on Artificial Intelligence in 2019. Amongst them is an expectation of advancement in AI-enabled drug trials.